Effect of oral glucosamine on joint structure in individuals with chronic knee pain: A randomized, placebo-controlled clinical trial

Arthritis and Rheumatology

Volumn 66, Issue 4, 2014, Pages 930-939

  Kwoh, C Kent ^a,b   Roemer, Frank W ^c,e   Hannon, Michael J ^a   Moore, Carolyn E ^d   Jakicic, John M ^a   Guermazi, Ali ^b   Green, Stephanie M ^a   Evans, Rhobert W ^a   Boudreau, Robert ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c BOSTON UNIVERSITY   (United States)

^d TEXAS WOMAN'S UNIVERSITY   (United States)

^e KLINIKUM AUGSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; GLUCOSAMINE; PLACEBO; TELOPEPTIDE;

ADULT; AGED; ARTICLE; BONE MARROW DISEASE; CARBOXY TERMINAL SEQUENCE; CARTILAGE INJURY; CHRONIC PAIN; CONTROLLED STUDY; CROSS LINKING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; JOINT; KNEE PAIN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIGRAINE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; UNITED STATES; WEIGHT GAIN; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; CARTILAGE, ARTICULAR; CHRONIC PAIN; DOUBLE-BLIND METHOD; FEMALE; GLUCOSAMINE; HUMANS; KNEE JOINT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; TREATMENT OUTCOME;

EID: 84898634956     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38314     Document Type: Article

References (54)

1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al, for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II. Arthritis Rheum 2008; 58: 26-35.
2. Kotlarz H, Gunnarsson CL, Fang H, Rizzo JA,. Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data. Arthritis Rheum 2009; 60: 3546-53.
3. Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010; 18: 476-99.
4. Barnes PM, Bloom B, Nahin RL,. Complementary and alternative medicine use among adults and children: United States, 2007. National health statistics reports, no. 12. Hyattsville (MD): National Center for Health Statistics, 2008. URL: http://nccam.nih.gov/sites/nccam.nih.gov/files/news/nhsr12.pdf/.
5. Glucosamine. URL: http://www.nutraingredients-usa.com/Markets/Why-US- glucosamine-sales-are-slow.
6. Brandt KD, Dieppe P, Radin EL,. Etiopathogenesis of osteoarthritis. Rheum Dis Clin North Am 2008; 34: 531-59.
7. Altman RD, Abramson S, Bruyere O, Clegg D, Herrero-Beaumont G, Maheu E, et al. Commentary: osteoarthritis of the knee and glucosamine. Osteoarthritis Cartilage 2006; 14: 963-6.
8. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354: 795-808.
9. Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, Blanco FJ, Benito P, Martin-Mola E, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007; 56: 555-67.
10. McAlindon T, Formica M, LaValley M, Lehmer M, Kabbara K,. Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomized double-blind controlled trial. Am J Med 2004; 117: 643-9.
11. Poolsup N, Suthisisang C, Channark P, Kittikulsuth W,. Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials. Ann Pharmacother 2005; 39: 1080-7.
12. Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY,. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003; 163: 1514-22.
13. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Bingham CO III, Harris CL, et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis Rheum 2008; 58: 3183-91.
14. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005:CD002946.
15. Wandel S, Juni P, Tendal B, Nuesch E, Villiger PM, Welton NJ, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010; 341: c4675.
16. Treatment of primary and secondary osteoarthritis of the knee. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2007 Sept. Publication No. 07-E012.
17. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC,. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113-23.
18. Vlad SC, LaValley MP, McAlindon TE, Felson DT,. Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum 2007; 56: 2267-77.
19. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 251-6.
20. Amin S, LaValley MP, Guermazi A, Grigoryan M, Hunter DJ, Clancy M, et al. The relationship between cartilage loss on magnetic resonance imaging and radiographic progression in men and women with knee osteoarthritis. Arthritis Rheum 2005; 52: 3152-9.
21. Conaghan PG, Hunter DJ, Maillefert JF, Reichmann WM, Losina E,. Summary and recommendations of the OARSI FDA osteoarthritis Assessment of Structural Change Working Group. Osteoarthritis Cartilage 2011; 19: 606-10.
22. Bijlsma JW, Lafeber FP,. Glucosamine sulfate in osteoarthritis: the jury is still out. Ann Intern Med 2008; 148: 315-6.
23. Guermazi A, Burstein D, Conaghan P, Eckstein F, Hellio Le Graverand-Gastineau MP, Keen H, et al. Imaging in osteoarthritis. Rheum Dis Clin North Am 2008; 34: 645-87.
24. Jung M, Christgau S, Lukoschek M, Henriksen D, Richter W,. Increased urinary concentration of collagen type II C-telopeptide fragments in patients with osteoarthritis. Pathobiology 2004; 71: 70-6.
25. Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004; 50: 2471-8.
26. Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, et al. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage 2011; 19: 515-42.
27. Dam EB, Byrjalsen I, Karsdal MA, Qvist P, Christiansen C,. Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage 2009; 17: 384-9.
28. Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002; 46: 2613-24.
29. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW,. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 1833-40.
30. Kellgren JH, Lawrence JS,. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16: 494-502.
31. Mattes RD, Popkin BM,. Nonnutritive sweetener consumption in humans: effects on appetite and food intake and their putative mechanisms. Am J Clin Nutr 2009; 89: 1-14.
32. Peterfy CG, Schneider E, Nevitt M,. The Osteoarthritis Initiative: report on the design rationale for the magnetic resonance imaging protocol for the knee. Osteoarthritis Cartilage 2008; 16: 1433-41.
33. Peterfy CG, Guermazi A, Zaim S, Tirman PF, Miaux Y, White D, et al. Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage 2004; 12: 177-90.
34. Roemer FW, Nevitt MC, Felson DT, Niu J, Lynch JA, Crema MD, et al. Predictive validity of within-grade scoring of longitudinal changes of MRI-based cartilage morphology and bone marrow lesion assessment in the tibio-femoral joint-the MOST study. Osteoarthritis Cartilage 2012; 2012: 1391-8.
35. Roemer FW, Guermazi A, Javaid MK, Lynch JA, Niu J, Zhang Y, et al. Change in MRI-detected subchondral bone marrow lesions is associated with cartilage loss: the MOST Study. A longitudinal multicentre study of knee osteoarthritis. Ann Rheum Dis 2009; 68: 1461-5.
36. Roemer FW, Nevitt MC, Felson DT, Niu J, Lynch J, Crema M, et al. Validity of within-grade scoring of longitudinal changes of MRI-based cartilage morphology and bone marrow lesion assessment-the MOST study [abstract]. Arthritis Rheum 2011; 63: S779.
37. Roemer FW, Zhang Y, Niu J, Lynch JA, Crema MD, Marra MD, et al, for the Multicenter Osteoarthritis (MOST) Study Investigators. Tibiofemoral joint osteoarthritis: risk factors for MRdepicted fast cartilage loss over a 30-month period in the Multicenter Osteoarthritis study. Radiology 2009; 252: 772-80.
38. Heinegard D, Tiderstrom G,. Determination of serum creatinine by a direct colorimetric method. Clin Chim Acta 1973; 43: 305-10.
39. Peterfy C, Li J, Zaim S, Duryea J, Lynch J, Miaux Y, et al. Comparison of fixed-flexion positioning with fluoroscopic semi-flexed positioning for quantifying radiographic joint-space width in the knee: test-retest reproducibility. Skeletal Radiol 2003; 32: 128-32.
40. Altman RD, Gold GE,. Atlas of individual radiographic features in osteoarthritis, revised. Osteoarthritis Cartilage 2007; 15 Suppl A: A1-56.
41. Bruyere O, Genant H, Kothari M, Zaim S, White D, Peterfy C, et al. Longitudinal study of magnetic resonance imaging and standard x-rays to assess disease progression in osteoarthritis. Osteoarthritis Cartilage 2007; 15: 98-103.
42. Wildi LM, Raynauld JP, Martel-Pelletier J, Abram F, Dorais M, Pelletier JP,. Relationship between bone marrow lesions, cartilage loss and pain in knee osteoarthritis: results from a randomised controlled clinical trial using MRI. Ann Rheum Dis 2010; 69: 2118-24.
43. Kubota M, Ishijima M, Kurosawa H, Liu L, Ikeda H, Osawa A, et al. A longitudinal study of the relationship between the status of bone marrow abnormalities and progression of knee osteoarthritis. J Orthop Sci 2010; 15: 641-6.
44. Laslett LL, Dore DA, Quinn SJ, Boon P, Ryan E, Winzenberg TM, et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis 2012; 71: 1322-8.
45. Garnero P, Peterfy C, Zaim S, Schoenharting M,. Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum 2005; 52: 2822-9.
46. Bruyere O, Collette J, Kothari M, Zaim S, White D, Genant H, et al. Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study. Ann Rheum Dis 2006; 65: 1050-4.
47. Wildi LM, Raynauld JP, Martel-Pelletier J, Beaulieu A, Bessette L, Morin F, et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011; 70: 982-9.
48. Dawson J, Linsell L, Zondervan K, Rose P, Randall T, Carr A, et al. Epidemiology of hip and knee pain and its impact on overall health status in older adults. Rheumatology (Oxford) 2004; 43: 497-504.
49. Roemer FW, Crema MD, Trattnig S, Guermazi A,. Advances in imaging of osteoarthritis and cartilage. Radiology 2011; 260: 332-54.
50. Hunter DJ, Bowes MA, Eaton CB, Holmes AP, Mann H, Kwoh CK, et al. Can cartilage loss be detected in knee osteoarthritis (OA) patients with 3-6 months' observation using advanced image analysis of 3T MRI? Osteoarthritis Cartilage 2010; 18: 677-83.
51. Wildi LM, Martel-Pelletier J, Abram F, Moser T, Raynauld JP, Pelletier JP,. Assessment of cartilage changes over time in knee osteoarthritis disease-modifying osteoarthritis drug trials using semiquantitative and quantitative methods: pros and cons. Arthritis Care Res (Hoboken) 2013; 65: 686-94.
52. Altman RD,. Glucosamine therapy for knee osteoarthritis: pharmacokinetic considerations. Expert Rev Clin Pharmacol 2009; 2: 359-71.
53. Block JA, Oegema TR, Sandy JD, Plaas A,. The effects of oral glucosamine on joint health: is a change in research approach needed? Osteoarthritis Cartilage 2010; 18: 5-11.
54. Ivanovska N, Dimitrova P,. Bone resorption and remodeling in murine collagenase-induced osteoarthritis after administration of glucosamine. Arthritis Res Ther 2011; 13: R44.